Bioconjugate Chemistry
Article
(3) Harms, J. F., Welch, D. R., Samant, R. S., Shevde, L. A., Miele, M.
E., Babu, G. R., Goldberg, S. F., Gilman, V. R., Sosnowski, D. M.,
Campo, D. A., Gay, C. V., Budgeon, L. R., Mercer, R., Jewell, J.,
Mastro, A. M., Donahue, H. J., Erin, N., Debies, M. T., Meehan, W. J.,
Jones, A. L., Mbalaviele, G., Nickols, A., Christensen, N. D., Melly, R.,
Beck, L. N., Kent, J., Rader, R. K., Kotyk, J. J., Pagel, M. D., Westlin, W.
F., and Griggs, D. W. (2004) A small molecule antagonist of the
alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis.
Clin. Exp. Metastasis 21, 119−128.
(4) Vellon, L., Menendez, J. A., and Lupu, R. (2006) A bidirectional
″alpha(v)beta(3) integrin-ERK1/ERK2MAPK″ connection regulates
the proliferation of breast cancer cells. Mol. Carcinog. 45, 795−804.
(5) Gingras, M. C., Roussel, E., Bruner, J. M., Branch, C. D., and
Moser, R. P. (1995) Comparison of cell adhesion molecule expression
between glioblastoma multiforme and autologous normal brain tissue.
J. Neuroimmunol. 57, 143−153.
(6) Albelda, S. M., Mette, S. A., Elder, D. E., Stewart, R.,
Damjanovich, L., Herlyn, M., and Buck, C. A. (1990) Integrin
distribution in malignant melanoma: association of the beta3 subunit
with tumor progression. Cancer Res. 50, 6757−6764.
(7) Dang, D., Bamburg, J. R., and Ramos, D. M. (2006) Alphavbeta3
integrin and cofilin modulate K1735 melanoma cell invasion. Exp. Cell
Res. 312, 468−477.
(8) Cooper, C. R., Chay, C. H., and Pienta, K. J. (2002) The role of
alpha(v)beta(3) in prostate cancer progression. Neoplasia 4, 191−194.
(9) Hapke, S., Kessler, H., Luber, B., Benge, A., Hutzler, P., Hofler,
H., Schmitt, M., and Reuning, U. (2003) Ovarian cancer cell
proliferation and motility is induced by engagement of integrin
alpha(v)beta3/vitronectin interaction. Biol. Chem. 384, 1073−1083.
(10) Auzzas, L., Zanardi, F., Battistini, L., Burreddu, P., Carta, P.,
Rassu, G., Curti, C., and Casiraghi, G. (2010) Targeting αVβ3 integrin:
design and applications of mono- and multifunctional RGD-based
peptides and semipeptides. Curr. Med. Chem. 17, 1255−1299.
(11) Paolillo, M., Russo, M. A., Serra, M., Colombo, L., and Schinelli,
S. (2009) Small molecule integrin antagonists in cancer therapy. Mini-
Rev. Med. Chem. 9, 1439−1446.
(12) Dechantsreiter, M. A., Planker, E., Matha, B., Lohof, E.,
Holzemann, G., Jonczyk, A., Goodmann, S. L., and Kessler, H. (1999)
N-Methylated cyclic RGD peptides as highly active and selective αVβ3
integrin antagonist. J. Med. Chem. 42, 3033−3040.
(13) Manzoni, L., Belvisi, L., Arosio, D., Civera, M., Pilkington-Miksa,
M., Potenza, D., Caprini, A., Araldi, E. M. V., Monferini, E., Mancino,
(19) Schottelius, M., Laufer, B., Kessler, H., and Wester, H.-J. (2009)
Ligands for mapping αVβ3-integrin expression in vivo. Acc. Chem. Res.
42, 969−980.
(20) Garanger, E., Boturyn, D., and Dumy, P. (2007) Tumor
targeting with RGD peptide ligands − Design of new molecular
conjugates for imaging and therapy of cancers. Anti Cancer Agents Med.
Chem. 7, 552−558.
(21) Temming, K., Schiffelers, R. M., Molema, G., and Kok, R. J.
(2005) RGD-Based strategies for selective delivery of therapeutics and
imaging agents to the tumor vasculature. Drug Resistance Updates 8,
381−402.
(22) Arap, W., Pasqualini, R., and Ruoslahti, E. (1998) Cancer
treatment by targeted drug delivery to tumor vasculature in a mouse
model. Science 279, 377−380.
(23) Liu, Y., Bajjuri, K. M., Liu, C., and Sinha, S. C. (2012) Targeting
cell surface alpha(v)beta(3,5) integrins increases therapeutic efficacies
of a legumain protease-activated auristatin prodrug. Mol. Pharm. 9,
168−175.
(24) Dufort, S., Sancey, L., Hurbin, A., Foillard, S., Boturyn, D.,
Dumy, P., and Coll, J.-L. (2011) Targeted delivery of a proapoptotic
peptide to tumors in vivo. J. Drug Targeting 19, 582−588.
(25) Dal Pozzo, A., Esposito, E., Ni, M., Muzi, L., Pisano, C., Bucci,
F., Vesci, L., Castorina, M., and Penco, S. (2010) Conjugates of a novel
7-substituted camptothecin with RGD-peptides as αVβ3 integrin
ligands: an approach to tumor-targeted therapy. Bioconjugate Chem.
21, 1956−1967.
(26) Braun, K., Wiessler, M., Pipkorn, R., Ehemann, V., Bauerle, T.,
̈
Fleischhacker, H., Muller, G., Lorenz, P., and Waldeck, W. (2010) A
̈
cyclic-RGD-BioShuttle functionalized with TMZ by DARinv “Click
Chemistry” targeted to αVβ3 integrin for therapy. Int. J. Med. Sci. 7,
326−339.
(27) Ryppa, C., Mann-Steinberg, H., Biniossek, M. L., Satchi-Fainaro,
R., and Kratz, F. (2009) In vitro and in vivo evaluation of a paclitaxel
conjugate with the divalent peptide E-[c(RGDfK)2] that targets
integrin αVβ3. Int. J. Pharm. 368, 89−97.
(28) Chen, X., Plasencia, C., Hou, Y., and Neamati, N. (2005)
Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel
conjugate as a model for integrin-targeted drug delivery. J. Med. Chem.
48, 1098−1106. (corrigendum (2005) J. Med. Chem. 48, 5874).
(29) Cao, Q., Li, Z.-B., Chen, K., Wu, Z., He, L., Neamati, N., and
Chen, X. (2008) Evaluation of biodistribution and anti-tumor effect of
a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer.
Eur. J. Nucl. Med. Mol. Imaging 35, 1489−1498.
(30) Arosio, D., Casagrande, C., and Manzoni, L. (2012) Integrin-
mediated drug delivery in cancer and cardiovascular diseases with
peptide-functionalized nanoparticles. Curr. Med. Chem. 19, 3128−
3151.
(31) Zhan, C., Meng, Q., Li, Q., Feng, L., Zhu, J., and Lu, W. (2012)
Cyclic RGD−Polyethylene Glycol−Polyethylenimine for Intracranial
Glioblastoma-Targeted Gene Delivery. Chem. Asian J. 7, 91−96.
(32) Yao, H.-J., Ju, R.-J., Wang, X.-X., Zhang, Y., Li, R.-J., Yu, Y.,
Zhang, L., and Lu, W.-L. (2011) The antitumor efficacy of functional
paclitaxel nanomicelles in treating resistant breast cancers by oral
delivery. Biomaterials 32, 3285−3302.
̀
M., Podesta, F., and Scolastico, C. (2009) Cyclic RGD-containing
functionalized azabicycloalkane peptides as potent integrin antagonists
for tumor targeting. ChemMedChem 4, 615−632.
(14) Battistini, L., Burreddu, P., Carta, P., Rassu, G., Auzzas, L., Curti,
C., Zanardi, F., Manzoni, L., Araldi, E. M. V., Scolastico, C., and
Casiraghi, G. (2009) 4-Aminoproline-based arginine-glycine-aspartate
integrin binders with exposed ligation points: practical in-solution
synthesis, conjugation and binding affinity evaluation. Org. Biomol.
Chem. 7, 4924−4935.
(15) Liu, Z., Wang, F., and Chen, X. (2008) Integrin αVβ3-targeted
cancer therapy. Drug Dev. Res. 69, 329−339.
(16) Stupp, R., and Ruegg, C. (2007) Integrin inhibitors reaching the
clinic. J. Clin. Oncol. 25, 1637−1638.
(17) Reardon, D. A., Fink, K. L., Mikkelsen, T., Cloughesy, T. F.,
O’Neill, A., Plotkin, S., Glantz, M., Ravin, P., Raizer, J. J., Rich, K. M.,
Schiff, D., Shapiro, W. R., Burdette-Radoux, S., Dropcho, E. J.,
Wittemer, S. M., Nippgen, J., Picard, M., and Nabors, B. L. (2008)
Randomized phase II study of cilengitide, an integrin-targeting
arginine-glycine-aspartic acid peptide, in recurrent glioblastoma
multiforme. J. Clin. Oncol. 26, 5610−5617.
(18) MacDonald, T. J., Stewart, C. F., Kocak, M., Goldman, S.,
Ellenbogen, R. G., Phillips, P., Lafond, D., Young Poussaint, T., Kieran,
M. W., Boyett, J. M., and Kun, L. E. (2008) Phase I clinical trial of
Cilengitide in children with refractory brain tumors: pedriatric brain
tumor consortium study PBTC-012. J. Clin. Oncol. 26, 919−924.
(33) Eldar-Boock, A., Miller, K., Sanchis, J., Lupu, R., Vicent, M. J.,
and Satchi-Fainaro, R. (2011) Integrin-assisted drug delivery of nano-
scaled polymer therapeutics bearing paclitaxel. Biomaterials 32, 3862−
3874.
(34) Austin, L. A., Kang, B., Yen, C.-W., and El-Sayed, M. A. (2011)
Nuclear targeted silver nanospheres perturb the cancer cell cycle
differently than those of nanogold. Bioconjugate Chem. 22, 2324−2331.
(35) Ubezio, P., Garofalo, A., Borsotti, P., Cassis, L., Riccardi, E.,
Scanziani, E., Eccles, S. A., Bani, M. R., and Giavazzi, R. (2006) The
vascular targeting property of paclitaxel is enhanced by SU6668, a
receptor tyrosine kinase inhibitor, causing apoptosis of endothelial
cells and inhibition of angiogenesis. Clin. Cancer Res. 12, 1839−1849.
(36) Dijkgraaf, I., Rijnders, A. Y., Soede, A., Dechesne, A. C., van
Esse, G. W., Brouwer, A. J., Corstens, F. H. M., Boerman, O. C.,
Rijkers, D. T. S., and Liskamp, R. M. (2007) Synthesis of DOTA-
1621
dx.doi.org/10.1021/bc300164t | Bioconjugate Chem. 2012, 23, 1610−1622